Table 2 Hepatitis B Practices related survey questions
From: Management of hepatitis B infected pregnant women: a cross-sectional study of obstetricians
Questions | n (%) | ||
|---|---|---|---|
(Q1) | Have you ever had a pregnant patient who tested positive for HBsAg? | Yes | 122 (88.4) |
No | 10 (7.2) | ||
Don’t know/no response | 6 (4.4) | ||
Screening | |||
(Q2) | Do you or your clinic routinely test all pregnant women for HBsAg with each pregnancy, regardless of results? | Yes | 130 (94.2) |
No | 1 (0.7) | ||
Don’t know/no response | 7 (5.1) | ||
(Q3) | Do you routinely inform HBsAg-positive pregnant women that their household and sexual contacts should be tested for hepatitis B? | Yes | 105 (76.1) |
No | 17 (12.3) | ||
Don’t know/no response | 16 (11.6) | ||
Reporting | |||
(Q4) | Do you or your clinic routinely include a lab copy of the pregnant patient’s HBsAg test result in the medical record sent to the birth hospital prior to the expected delivery date? | Yes | 89 (64.5) |
No | 33 (23.9) | ||
Don’t know/no response | 16 (11.6) | ||
(Q5) | Do you know that California state ordinance requires all physicians to report positive HBsAg test results to the county health department? | Yes | 105 (76.1) |
No | 33 (23.9) | ||
Don’t know/no response | 0 (0.0) | ||
Vaccination | |||
(Q6) | Do you routinely inform HBsAg-positive pregnant women that it is important for their newborn infants to receive hepatitis B immune globulin within 12 h of delivery to prevent perinatal hepatitis B transmission? | Yes | 124 (89.8) |
No | 2 (1.4) | ||
Don’t know/no response | 12 (8.7) | ||
(Q7) | Do you routinely inform HBsAg-positive pregnant women that it is important for their newborn infants to receive a birth dose of the hepatitis B vaccine within 12 h of delivery to prevent perinatal hepatitis B transmission? | Yes | 121 (87.7) |
No | 3 (2.2) | ||
Don’t know/no response | 14 (10.1) | ||
(Q8) | Do you routinely inform HBsAg-positive pregnant women that their infants need to receive the 2nd and 3rd doses of the hepatitis B vaccine at 1–2 months and 6 months of age? | Yes | 67 (48.6) |
No | 49 (35.5) | ||
Don’t know/no response | 22 (15.9) | ||
(Q9) | Do you routinely inform HBsAg-positive pregnant women that their infants should be tested for HBsAg and hepatitis B surface antibody between 9 and 18 months of age to ascertain whether the infants are immune or have been infected? | Yes | 28 (20.3) |
No | 78 (56.5) | ||
Don’t know/no response | 32 (23.2) | ||
Patient Education | |||
(Q10) | Do you or your clinic routinely provide educational information about hepatitis B to HBsAg-positive pregnant patients? | Yes | 67 (48.6) |
No | 30 (21.7) | ||
Don’t know/no response | 41 (29.7) | ||
Monitoring Of Hepatitis During Pregnancy | |||
(Q11) | Do you routinely measure hepatitis B DNA and/or hepatitis B e-antigen levels in HBsAg-positive pregnant patients? | Yes | 88 (63.8) |
No | 32 (23.2) | ||
Don’t know/no response | 18 | ||
(Q12) | Do you routinely monitor HBsAg-positive pregnant women by performing liver enzyme tests during pregnancy? | Yes | 107 (77.5) |
No | 14 (10.1) | ||
Don’t know/no response | 17 (12.4) | ||
Referral For Chronic HBV Management | |||
(Q13) | Do you routinely advise HBsAg-positive pregnant women to consult with a liver specialist or internist for evaluation for anti-viral therapy and lifelong monitoring for liver damage and liver cancer? | Yes | 84 (60.9) |
No | 29 (21.0) | ||
Don’t know/no response | 25 (18.1) | ||